reports
GLAND PHARMA sees an upgrade to Slightly Positive due to a better fund...
The general evaluation of GLAND PHARMA (IN), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 5, 2021, the closing price was INR 4,030...
- Tushar Manudhane
MOSL: GLAND PHARMA (Buy)-Complex products/newer markets to fortify gro...
GLAND PHARMA: Complex products/newer markets to fortify growth pace (GLAND IN, Mkt Cap USD8.4b, CMP INR3802, TP INR4460, 17% Upside, Buy) Progressing well on scaling up manufacturing of the vaccine GLAND’s 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.